Price movement over the last 24 hours
ARK Space & Defense Innovation ETF vs FMC Corp — how do they compare? ARK Space & Defense Innovation ETF trades at $31.76, while FMC Corp trades at $10.92 (market cap $1.37B). The key difference: FMC Corp pays a 2.93% dividend while ARK Space & Defense Innovation ETF pays none, and ARK Space & Defense Innovation ETF is trading nearer its 52-week high, FMC Corp nearer its low. Which is the better fit depends on your goals.
| ARKX | FMC | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $37.74 | $43.90 |
52-Week Low | $24.97 | $10.80 |
Market Cap | — | $1.37B |
Enterprise Value | — | $5.51B |
Dividend Yield | — | 2.93% |
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
FMC Corporation (FMC) trades at $10.91, showing minimal daily movement with a 0.18% gain. The stock faces significant fundamental challenges, including a net loss of -$2.24 billion in 2025 and negative profit margins, though recent strategic moves like a $400 million investment from Tessenderlo Group and asset sales aim to reduce debt. Technical indicators are bearish, with the stock trading near key support levels. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings but a consensus price target of $17.00 suggesting substantial upside potential from current levels.
The outlook for FMC hinges on successful debt reduction and the commercial success of new products like rimisoxafen. While the current valuation metrics (P/S: 0.4, P/B: 0.75) appear attractive, the deeply negative profitability and high debt load present significant risks. The potential for a operational turnaround exists, but investors should weigh the high risk of continued losses against the possibility of a recovery driven by new technology and improved financial health.
Trailing returns across standard periods
Latest headlines on both assets
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →